Zimmer Biomet : Announces Successful Completion of World’s First Robotic-Assisted Shoulder Replacement Surgery with ROSA® Shoulder System

print-link

Zimmer Biomet Announces Successful Completion of World's First Robotic-Assisted Shoulder Replacement Surgery with ROSA® Shoulder System Zimmer Biomet Announces Successful Completion of World's First Robotic-Assisted Shoulder Replacement Surgery with ROSA® Shoulder System

Apr 25, 2024

(WARSAW, Ind.,) April 25, 2024 - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the successful completion of the world's first robotic-assisted shoulder replacement surgery using its ROSA^® Shoulder System. The surgery was performed at Mayo Clinic by John W. Sperling, MD, MBA, Professor of Orthopedic Surgery at Mayo Clinic in Rochester, Minnesota, and a key contributor to the ROSA Shoulder development team.

"The debut of ROSA Shoulder marks an incredible milestone for Zimmer Biomet and we are honored to have the first patient case performed by Dr. Sperling, who is widely recognized for his practiced expertise in shoulder reconstruction," said Ivan Tornos, President and Chief Executive Officer at Zimmer Biomet. "ROSA Shoulder reinforces our dedicated pursuit to deliver first-to-world innovative solutions that help surgeons perform complex orthopedic procedures."

"Adding robotic surgical assistance to shoulder replacement surgery has the potential to transform intra-operative and post-operative outcomes, while improving the overall patient experience," said Dr. Sperling.

ROSA Shoulder received U.S. FDA 510(k) clearance in February of 2024, and is designed to give surgeons the flexibility to execute a total shoulder replacement using anatomic or reverse techniques and to enable precise placement.³ Like all ROSA Robotics applications, ROSA Shoulder is designed to support data-informed physician decision-making based on a patient's unique anatomy. Pre-operatively, ROSA Shoulder integrates with the newly released Signature™ ONE 2.0 Surgical Planning System, which uses a 3-D image-based approach for visualization of humeral and glenoid anatomy, and surgical planning. During the surgery, the platform provides surgeons with real-time, intra-operative data to help control, execute and validate personalized plans for accurate glenoid and humeral implant placement.3 The goal is to reduce risk of complications for the patient, enhance the clinical outcome and improve patient satisfaction.^4,5,6,7

ROSA Shoulder bolsters ZBEdge™ Dynamic Intelligence™ solutions, which leverage cutting-edge technology paired with our robust portfolio of shoulder implant systems to offer patients a highly personalized experience.

To learn more about ROSA Shoulder, visit zimmerbiomet.com/ROSAShoulder.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

+++

About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

References

¹ AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report. Updated 2023. 2023.

² NJR-UK. (2022). The National Joint Registry 19th Annual Report 2022 https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2019th%20Annual%20Report%202022.pdf

³ Data on File FER-JSB231211-01 Rev. A. Cadaveric studies are not necessarily indicative of clinical performance.

⁴ Gregory TM, Sankey A, Augereau B, Vandenbussche E, Amis A, Emery R, Hansen U. Accuracy of glenoid component placement in total shoulder arthroplasty and its effect on clinical and radiological outcome in a retrospective, longitudinal, monocentric open study. PLoS One 8(10): e75791, 2013.

⁵ Chalmers PN, Boileau P, Romeo AA, Tashjian RZ. Revision Reverse Shoulder Arthroplasty. J Am Acad Orthop Surg. 2019 Jun 15;27(12):426-436. doi: 10.5435/JAAOS-D-17-00535. PMID: 31170096.

⁶ Franta AK, Lenters TR, Mounce D, Neradilek B, Matsen FA 3rd. The complex characteristics of 282 unsatisfactory shoulder arthroplasties. J Shoulder Elbow Surg. 2007 Sep-Oct;16(5):555-62. doi: 10.1016/j.jse.2006.11.004. Epub 2007 May 16. PMID: 17509905.

⁷ Duethman NC, Aibinder WR, Nguyen NTV, Sanchez-Sotelo J. The influence of glenoid component position on scapular notching: a detailed radiographic analysis at midterm follow-up. JSES Int. 2020 Jan 14;4(1):144-150. doi: 10.1016/j.jses.2019.11.004. PMID: 32195477; PMCID: PMC7075770.

Media

Heather Zoumas-Lubeski

445-248-0577

[e-mail]

Investors

Zach Weiner

908-591-6955

[e-mail]

<< Back to 2024